Supreme Court rebuffs another J&J appeal, leaving $140M failure-to-warn judgment intact

Tracy Staton

Johnson & Johnson is zero for two at the U.S. this month. Last week, the refused to weigh its final against a $ 124 million penalty in a Risperdal marketing case. Now, the high has said the same about an even bigger .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS